We are live on ! Find out more
ZVRA icon

Zevra Therapeutics
ZVRA

40 hedge funds and large institutions have $29M invested in Zevra Therapeutics in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

17% more capital invested

Capital invested by funds: $24.8M → $29M (+$4.11M)

0% more funds holding

Funds holding: 40 → 40 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
40
Holders Change
–
Holders Change %
0%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
12
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Creative Planning
Creative Planning
Kansas
+$1.79M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$688K
3
PL
Parkwood LLC
Ohio
+$440K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$117K
5
BFA
BlackRock Fund Advisors
California
+$58.6K

Top Sellers

1
DM
Deerfield Management
New York
-$1.49M
2
SIM
Spark Investment Management
New York
-$494K
3
Millennium Management
Millennium Management
New York
-$155K
4
TC
TFS Capital
Pennsylvania
-$53K
5
ProShare Advisors
ProShare Advisors
Maryland
-$43K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$36K +$35.6K +500 New
BA
27
BlackRock Advisors
Delaware
$19K +$17K +239 +996%
Deutsche Bank
28
Deutsche Bank
Germany
$18K -$6.54K -92 -26%
Morgan Stanley
29
Morgan Stanley
New York
$17K -$640 -9 -4%
TRCT
30
Tower Research Capital (TRC)
New York
$15K +$14.9K +210 New
Citigroup
31
Citigroup
New York
$11K +$2.77K +39 +36%
BIM
32
BlackRock Investment Management
Delaware
$9K – – –
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$9K – – –
WCM
34
Wealthcare Capital Management
Virginia
$9K – – –
TIM
35
Tortoise Investment Management
New York
$8K – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$8K +$7.47K +105 New
CG
37
Cutler Group
California
$3K – – –
Manulife (Manufacturers Life Insurance)
38
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K – – –
TC
39
TFS Capital
Pennsylvania
– -$53K -837 Closed
ProShare Advisors
40
ProShare Advisors
Maryland
– -$43K -681 Closed
CS
41
Credit Suisse
Switzerland
– -$41K -647 Closed
Bank of America
42
Bank of America
North Carolina
– -$6.33K -89 -99%
Barclays
43
Barclays
United Kingdom
– -$498 -7 -64%
1
2

ZVRA Hedge Fund Activity: Q3 2016 in Review

40 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2016, worth a combined $29M — up 17% from $24.8M a quarter earlier.

Fund positioning in ZVRA was balanced in Q3 2016: 3 funds opened new positions, 3 closed out, 12 added to existing stakes and 10 trimmed.

The largest buyer was Creative Planning, adding an estimated $1.79M. The largest seller was Deerfield Management, cutting an estimated $1.49M.

  • 40 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $29M of Zevra Therapeutics stock for Q3 2016, up 17% quarter-over-quarter.
  • 3 funds opened new Zevra Therapeutics positions in Q3 2016 and 3 closed out, a net change of 0 holders.
  • The largest Zevra Therapeutics buyer in Q3 2016 was Creative Planning, an estimated $1.79M added.
  • The largest Zevra Therapeutics seller in Q3 2016 was Deerfield Management, an estimated $1.49M sold.

Based on aggregated 13F filings for Q3 2016.